Clearly a blockbuster consolidating move within the instrumentation and consumables space, the April acquisition of Life Technologies Corp. by Thermo Fisher Scientific Inc. is also a sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth. As well, it reflects the desire to move genomics tools into clinical use and the interest among nontraditional players in pursuing diagnostics.
Thermo Fisher won a four-month bidding war for LifeTech, agreeing to shell out $13 billion in cash plus assumption of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?